<p>/PRNewswire/ -- 在 2025 年 12 月 11 日，Rezolute, Inc. <strong>(NASDAQ: RZLT)</strong> 的投资者在公司披露其 ersodetug（&#34;erso&#34;）的第三阶段 sunRIZE 试验失败后，股价在盘中交易中暴跌了多达 90%。</p>
<p>该公司将这种药物宣传为一种潜在的治疗由高胰岛素血症（&#34;HI&#34;）引起的低血糖的药物。</p>
<p>这一消息、分析师的举动以及市场的剧烈反应促使全国股东权益公司 Hagens Berman 对 Rezolute 是否曾误导投资者关于 erso 的疗效和商业前景展开调查。</p>
<p>该公司敦促在 Rezolute 遭受重大损失的投资者立即提交损失。该公司还鼓励有知识的人士与其律师联系，以协助调查。</p>
<p><strong>访问：</strong> www.hbsslaw.com/investor-fraud/rzlt <strong>立即联系该公司：</strong>[email protected]</p>
<p><strong>844-916-0895</strong></p>
<p><strong>Rezolute, Inc. (RZLT) 调查：</strong></p>
<p>就在 11 月中旬，Rezolute 向投资者保证，&#34;在现实世界环境以及临床研究中，erso 显示出显著消除低血糖并改善高胰岛素血症患者生活质量的潜力 []&#34;，并且第三阶段研究&#34;有望严格证明 ersodetug 的疗效和安全性 [.]&#34;</p>
<p>该公司还表示，&#34;一个令人难以置信的市场机会 […] 摆在我们面前 []&#34;，并且在验证当前市场假设后，它&#34;拥有比最初预期更大的市场机会 [.]&#34;</p>
<p>投资者的失望在 2025 年 12 月 11 日突然袭来。那天，Rezolute 震惊了他们，当公司宣布第三阶段试验结果时，这些结果似乎与之前的保证相悖。公司表示，该研究未能达到其主要终点，与安慰剂相比，低血糖事件的减少在统计上并不显著。此外，erso 在与安慰剂相比时未能达到其次要终点（评估通过连续血糖监测的低血糖平均每日百分比时间的变化）。</p>
<p>市场迅速反应，Rezolute 的股价当天暴跌了多达 90%。分析师们也迅速做出反应，有一位分析师将 Rezolute 的评级从跑赢大盘下调至中性，目标价从 12 美元下调至 1 美元。</p>
<p>&#34;我们关注 Rezolute 是否可能误导投资者关于 erso 的真实疗效和商业前景的程度，&#34;Hagens Berman 的合伙人 Reed Kathrein 表示，他正在领导该公司的调查。</p>
<p>如果您投资了 Rezolute 并遭受了重大损失，或者有可能协助该公司调查的信息，请立即提交您的损失 »</p>
<p>如果您想了解更多信息以及关于 Rezolute 调查的常见问题的答案，请阅读更多 »</p>
<p><strong>举报人：</strong> 了解 Rezolute 的非公开信息的人士应考虑他们的选择，以帮助调查或利用 SEC 举报人计划。在新计划下，提供原始信息的举报人可能会获得高达 SEC 成功追回的 30% 的奖励。有关更多信息，请致电 Reed Kathrein，电话 <strong>844-916-0895</strong> 或发送电子邮件至 [email protected]。</p>
<p>关于 Hagens Berman</p>
<p>Hagens Berman 是一家全球性的原告权益复杂诉讼公司，专注于企业问责制。该公司拥有强大的业务，代表投资者、举报人、工人、消费者及其他在因企业疏忽和其他不当行为而受到伤害的案件中取得实际结果的人士。Hagens Berman 的团队在这一法律领域已获得超过 29 亿美元的赔偿。有关该公司及其成功的更多信息，请访问 hbsslaw.com。关注该公司以获取更新和新闻，推特账号为 @ClassActionLaw。</p>
<p>来源：Hagens Berman Sobol Shapiro LLP</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE4Jk5ld3NJdGVtSWQ9U0Y1MDkzMSZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTgxMzQ5UFJfTkVXU19VU1BSX19fX19TRjUwOTMx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE4Jk5ld3NJdGVtSWQ9U0Y1MDkzMSZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTgxMzQ5UFJfTkVXU19VU1BSX19fX19TRjUwOTMx"/></p>

RZLT

<p>Rezolute, Inc. (RZLT) 的股价在其针对低血糖潜在治疗药物 ersodetug 的第三阶段 sunRIZE 试验失败后暴跌 90%。Hagens Berman 正在调查 Rezolute 是否误导投资者关于该药物的疗效。该公司敦促受影响的投资者报告损失，并鼓励举报人协助调查。分析师已下调了对 Rezolute 的评级和价格目标。Hagens Berman 是一家专注于企业问责的诉讼公司</p>

<p>, /PRNewswire/ -- On December 11, 2025, investors in Rezolute, Inc. <strong>(NASDAQ: RZLT)</strong> saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its Phase 3 sunRIZE trial for ersodetug (&#34;erso&#34;).</p>
<div class="lb-trans"><p>/PRNewswire/ -- 在 2025 年 12 月 11 日，Rezolute, Inc. <strong>(NASDAQ: RZLT)</strong> 的投资者在公司披露其 ersodetug（&#34;erso&#34;）的第三阶段 sunRIZE 试验失败后，股价在盘中交易中暴跌了多达 90%。</p>
</div><p>The company has billed this drug as a potential treatment for hypoglycemia caused by hyperinsulinism (&#34;HI&#34;).</p>
<div class="lb-trans"><p>该公司将这种药物宣传为一种潜在的治疗由高胰岛素血症（&#34;HI&#34;）引起的低血糖的药物。</p>
</div><p>The news, analyst moves, and severe market reaction have prompted national shareholders rights firm Hagens Berman to open an investigation into whether Rezolute may have previously misled investors about erso's efficacy and commercial prospects.</p>
<div class="lb-trans"><p>这一消息、分析师的举动以及市场的剧烈反应促使全国股东权益公司 Hagens Berman 对 Rezolute 是否曾误导投资者关于 erso 的疗效和商业前景展开调查。</p>
</div><p>The firm urges investors in Rezolute who suffered significant losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.</p>
<div class="lb-trans"><p>该公司敦促在 Rezolute 遭受重大损失的投资者立即提交损失。该公司还鼓励有知识的人士与其律师联系，以协助调查。</p>
</div><p><strong>Visit:</strong> www.hbsslaw.com/investor-fraud/rzlt <strong>Contact the Firm Now:</strong>[email protected]</p>
<div class="lb-trans"><p><strong>访问：</strong> www.hbsslaw.com/investor-fraud/rzlt <strong>立即联系该公司：</strong>[email protected]</p>
</div><p><strong>844-916-0895</strong></p>
<div class="lb-trans"><p><strong>844-916-0895</strong></p>
</div><p><strong>Rezolute, Inc. (RZLT) Investigation:</strong></p>
<div class="lb-trans"><p><strong>Rezolute, Inc. (RZLT) 调查：</strong></p>
</div><p>As recently as mid-November, Rezolute assured investors that &#34;in both the real-world setting as well as in clinical studies, erso has shown the potential to substantially eradicate hypoglycemia and improve the quality of life for individuals living with hyperinsulinism[]&#34; and that the Phase 3 study &#34;is poised to be able to rigorously demonstrate the efficacy and safety of ersodetug[.]&#34;</p>
<div class="lb-trans"><p>就在 11 月中旬，Rezolute 向投资者保证，&#34;在现实世界环境以及临床研究中，erso 显示出显著消除低血糖并改善高胰岛素血症患者生活质量的潜力 []&#34;，并且第三阶段研究&#34;有望严格证明 ersodetug 的疗效和安全性 [.]&#34;</p>
</div><p>The company also said that an &#34;incredible market opportunity […] lies before us[]&#34; and that after validating the current market assumptions it has &#34;an even greater market opportunity than initially expected[.]&#34;</p>
<div class="lb-trans"><p>该公司还表示，&#34;一个令人难以置信的市场机会 […] 摆在我们面前 []&#34;，并且在验证当前市场假设后，它&#34;拥有比最初预期更大的市场机会 [.]&#34;</p>
</div><p>Investor disappointment abruptly set in on December 11, 2025. That day, Rezolute shocked them when the company announced results of the Phase 3 trial that appeared to contrast with previous assurances. The company said the study did not meet its primary endpoint and the reduction in hypoglycemia events was not statistically significant when compared to placebo. In addition, erso did not meet its secondary endpoint (which assessed change in average daily percent time in hypoglycemia by continuous glucose monitoring) when compared to placebo.</p>
<div class="lb-trans"><p>投资者的失望在 2025 年 12 月 11 日突然袭来。那天，Rezolute 震惊了他们，当公司宣布第三阶段试验结果时，这些结果似乎与之前的保证相悖。公司表示，该研究未能达到其主要终点，与安慰剂相比，低血糖事件的减少在统计上并不显著。此外，erso 在与安慰剂相比时未能达到其次要终点（评估通过连续血糖监测的低血糖平均每日百分比时间的变化）。</p>
</div><p>The markets swiftly reacted, sending the price of Rezolute shares crashing as much as 90% that day. Analysts also swiftly reacted, with one reportedly slashing Rezolute's rating from outperform to neutral and the price target from $12 to $1.</p>
<div class="lb-trans"><p>市场迅速反应，Rezolute 的股价当天暴跌了多达 90%。分析师们也迅速做出反应，有一位分析师将 Rezolute 的评级从跑赢大盘下调至中性，目标价从 12 美元下调至 1 美元。</p>
</div><p>&#34;We're focused on the degree to which Rezolute may have misled investors about erso's true efficacy and commercial prospects,&#34; said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.</p>
<div class="lb-trans"><p>&#34;我们关注 Rezolute 是否可能误导投资者关于 erso 的真实疗效和商业前景的程度，&#34;Hagens Berman 的合伙人 Reed Kathrein 表示，他正在领导该公司的调查。</p>
</div><p>If you invested in Rezolute and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now »</p>
<div class="lb-trans"><p>如果您投资了 Rezolute 并遭受了重大损失，或者有可能协助该公司调查的信息，请立即提交您的损失 »</p>
</div><p>If you'd like more information and answers to frequently asked questions about the Rezolute investigation, read more »</p>
<div class="lb-trans"><p>如果您想了解更多信息以及关于 Rezolute 调查的常见问题的答案，请阅读更多 »</p>
</div><p><strong>Whistleblowers:</strong> Persons with non-public information regarding Rezolute should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at <strong>844-916-0895</strong> or email [email protected].</p>
<div class="lb-trans"><p><strong>举报人：</strong> 了解 Rezolute 的非公开信息的人士应考虑他们的选择，以帮助调查或利用 SEC 举报人计划。在新计划下，提供原始信息的举报人可能会获得高达 SEC 成功追回的 30% 的奖励。有关更多信息，请致电 Reed Kathrein，电话 <strong>844-916-0895</strong> 或发送电子邮件至 [email protected]。</p>
</div><p>About Hagens Berman</p>
<div class="lb-trans"><p>关于 Hagens Berman</p>
</div><p>Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.</p>
<div class="lb-trans"><p>Hagens Berman 是一家全球性的原告权益复杂诉讼公司，专注于企业问责制。该公司拥有强大的业务，代表投资者、举报人、工人、消费者及其他在因企业疏忽和其他不当行为而受到伤害的案件中取得实际结果的人士。Hagens Berman 的团队在这一法律领域已获得超过 29 亿美元的赔偿。有关该公司及其成功的更多信息，请访问 hbsslaw.com。关注该公司以获取更新和新闻，推特账号为 @ClassActionLaw。</p>
</div><p>SOURCE Hagens Berman Sobol Shapiro LLP</p>
<div class="lb-trans"><p>来源：Hagens Berman Sobol Shapiro LLP</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE4Jk5ld3NJdGVtSWQ9U0Y1MDkzMSZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTgxMzQ5UFJfTkVXU19VU1BSX19fX19TRjUwOTMx" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=SF50931&amp;Transmission_Id=202512181349PR_NEWS_USPR_____SF50931&amp;DateId=20251218"/></p>

Rezolute, Inc. (RZLT) 的股价暴跌 90%，由于其主要资产的试验失败，Hagens Berman 正在进行调查